Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 clinical trial of IC-200 for treatment of BEST1 related retinal disease

Next Previous
Trial Profile

A Phase 1/2 clinical trial of IC-200 for treatment of BEST1 related retinal disease

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 22 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OPGx BEST1 (Primary)
  • Indications Vitelliform macular dystrophy
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 15 May 2025 According to an Opus Genetics media release, Opus plans to file an IND and begin a Phase 1/2 trial by the fourth quarter of 2025
  • 31 Mar 2025 According to an Opus Genetics media release, the company has planned to initiate this study in 2025, and to obtain its preliminary data by the first quarter of 2026.
  • 12 Nov 2024 According to an Opus Genetics media release, company anticipate filing a Clinical Trial Authorization (CTA) application in Germany in 2025 for commencement of a Phase 1/2 clinical trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top